8-KEarnings & ResultsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Jul 28, 2011)

Filed July 28, 2011For Securities:BMYCELG-RIBMYMP

Summary

This 8-K filing from Bristol-Myers Squibb (BMY) on July 28, 2011, primarily serves to announce the company's financial results for the second quarter of 2011. The report itself does not contain the detailed financial data but rather refers investors to an accompanying press release (Exhibit 99.1) and supplemental information available on the company's website (Exhibit 99.2) for the specific performance metrics. Investors should review these attached documents for a comprehensive understanding of the company's operational and financial condition during the quarter. The core purpose of this filing is to provide public disclosure of the company's quarterly performance. Investors seeking to assess BMY's financial health and operational success for the second quarter of 2011 will need to access the referenced press release and supplemental materials. These documents are expected to detail revenue, earnings, and other key financial indicators, offering insights into the company's business trajectory and potential impact on its stock.

Key Highlights

  • 1Bristol-Myers Squibb announced its second quarter 2011 financial results on July 28, 2011.
  • 2The 8-K filing incorporates by reference a press release detailing the Q2 2011 financial results (Exhibit 99.1).
  • 3Supplemental financial information, beyond the press release, is also furnished and available on the company's website (Exhibit 99.2).
  • 4The filing is primarily informational, directing investors to external documents for performance details.
  • 5No specific financial figures or operational highlights are provided directly within the 8-K text.
  • 6The event date for the earliest reported event is July 27, 2011.

Frequently Asked Questions

The 8-K filing itself does not contain the detailed financial results. Investors can find this information in the press release filed as Exhibit 99.1 and supplemental information on the company's website (Exhibit 99.2).

You will need to access Exhibit 99.1 (the press release) and Exhibit 99.2 (supplemental information) which are furnished with this 8-K filing. These documents are expected to contain the specific revenue, earnings, and other financial metrics for the quarter.

This 8-K filing is specifically focused on reporting the company's financial results and condition. It does not appear to contain details on strategic initiatives, mergers, acquisitions, or other significant business updates beyond what is disclosed in the referenced financial results documents.

The significance lies in the public disclosure of Bristol-Myers Squibb's quarterly financial performance. Investors should use this filing as a starting point to access the detailed Q2 2011 results, which are crucial for evaluating the company's operational health, profitability, and overall investment potential.